2017年Q4美国风险投资行业观察报告（英文版）_36页-4mb

2017 Venture Monitor Summary

Core Content

2017 was a record year for venture capital (VC) investment in the United States, with over $84.2 billion deployed into 1,772 companies in the fourth quarter alone. This marked the highest level of investment since the dot-com era and brought the annual total to $7,783 billion, the lowest since 2012 in terms of deal count but with a significant increase in total deal value (+16% YoY).

The venture ecosystem experienced notable changes in dynamics, including:

• Larger companies and later-stage financings: The median age of companies raising venture rounds increased significantly, especially at the early stages.
• Growth in deal sizes: Median deal sizes across all stages have grown, with early-stage rounds reaching $6 million and late-stage rounds hitting $11.4 million.
• Shift in investment focus: There was a notable increase in investment in biotech and fintech, with biotech reaching a 10-year high of $17.6 billion in funding.
• Unicorn activity: Unicorns (companies valued at over $1 billion) attracted $19.1 billion in 2017, representing 23% of total VC investment.
• IPO activity: The number of venture-backed IPOs increased from 41 in 2016 to 58 in 2017, but the expected resurgence in public market activity did not fully materialize.

Main Trends and Insights

1. Capital Deployment and Market Dynamics

• The VC industry has seen a surge in capital deployment, with more than $84 billion invested in the fourth quarter of 2017, the highest since the dot-com era.
• Despite fewer deals, the total value of transactions increased, indicating a shift toward larger, more valuable investments.
• The median age of companies receiving funding increased across all stages, reflecting a trend of later-stage financings and a longer time to liquidity.

2. Deal Size Growth

• Median deal sizes have grown significantly over the years, with early-stage rounds increasing by 20% and late-stage rounds rising by 14%.
• Rounds of $50 million and above accounted for nearly half of all VC investment in 2017, up from less than 20% in 2007.
• This growth is attributed to the availability of large pools of dry powder and a preference among investors for highly valued companies.

3. Sector Analysis

• Biotech and healthcare emerged as major growth areas, with $17.9 billion invested in life science companies, a 21% increase over 2015 and 48% over 2016.
• Fintech also saw significant investment, with the US fintech investment growing and attracting interest from both traditional and non-traditional investors.
• Software investment declined slightly after peaking in 2016, while AI, robotics, and blockchain remained strong areas of focus.
• Cryptocurrency gained traction, with over $4.2 billion raised via ICOs in 2017, leading to increased legal and institutional interest.

4. Investor Behavior and Market Evolution

• Investor discipline has increased, with fewer deals but higher valuations, indicating a more selective approach.
• SoftBank's Vision Fund played a pivotal role in the market, contributing to major deals such as WeWork and Compass, and potentially becoming the largest investor in Uber.
• Corporate VC and micro VC funds have become more prominent, with new funds raising significant capital and contributing to the growth of early-stage activity.
• The rise of secondary sales has become a key mechanism for providing liquidity to investors, management, and employees, although it remains a limited solution due to equity structure discrepancies.

5. Public Policy Impact

• FDA leadership changes, including the appointment of Scott Gottlieb, have had a positive impact on biotech innovation.
• The 2017 tax reform introduced provisions that may lead to increased M&A activity and support for startups and VC investors.

Key Players and Partners

• Silicon Valley Bank (SVB): Played a major role in supporting fintech and biotech ventures, with insights on debt vs. equity and startup financial strategies.
• Perkins Coie: Provided legal counsel for startups and investors, emphasizing the importance of token utility, management vetting, and setting realistic expectations for ICOs.
• Solium: Simplified equity management for early-stage companies, with a focus on cap table management and equity planning.

Conclusion

2017 was a pivotal year for the venture capital industry, marked by record-breaking deal values, a shift toward later-stage and biotech investments, and the growing influence of new capital sources such as SoftBank’s Vision Fund. While the IPO market remained subdued, the overall environment for venture-backed companies continued to evolve, with a greater emphasis on liquidity, KPIs, and institutionalization of early-stage investing.